Skip to content
Screener

G&A at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$8.1M+54.5%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$12.82M-13.2%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$13.1M+26.1%
Alumis Inc. logo
Alumis Inc.ALMS
$18.61M-16.5%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$13.44M-44.8%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$21.13M+19.7%

Segments

By segment

See full
VIASKIN® Peanut$14.6M+71.8%

By product

See full
Expenses by function$6.4M+64.1%

Other financials

Income statement

See full
Revenue$700.0K-53.3%
Operating income-$50.6M-23.1%
Net income-$50.4M-20.3%
EPS (diluted)-$0.12+61.3%

Balance sheet

See full
Cash & equivalents$174.9M+69.5%
Total debt$7.7M+0.1%
Total equity$160.4M+86.1%
Total assets$223.2M+55.6%

Cash flow

See full
Operating cash flow-$52.6M-55.2%
CapEx$400.0K
Free cash flow-$53.0M-56.3%

Valuation

See full
Market cap$847.16M+218%
Enterprise value$679.96M+297%
P/S168.8×+100×

Profitability

See full
Operating margin-3,543.1%+523pp
Net margin-3,506.5%+442pp
FCF margin-3,399.3%+3,268pp

Returns & leverage

See full
Return on equity-142.7%-5.0pp
Debt / equity0.0×
Current ratio3.7×+1.3×

Where this comes from

Reported directly by DBV Technologies in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: DBV Technologies’s 10-Q, filed July 16, 2026.

Filed
Jul 16, 2026, 4:08 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-048453
Line itemNoteThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Operating expenses13/17
Research and development expenses(31.2)(33.7)(64.6)(55.2)
Sales and marketing expenses(5.5)(0.4)(10.4)(0.7)
General and administrative expenses(14.6)(8.5)(25.1)(14.1)
Total Operating expenses(51.3)(42.6)(100.1)(69.9)
Loss from operations(50.6)(41.1)(98.5)(67.7)
Financial income (expense)0.4(0.6)0.9(1.1)
Loss before taxes(50.2)(41.8)(97.6)(68.8)

Item 1C. Condensed Consolidated Statements of Financial Position (Unaudited) as of

FAQ

What is DBV Technologies's G&A?
DBV Technologies (DBVT) reported G&A of $14.6M in Q2 2026.
How has DBV Technologies's G&A changed year-over-year?
DBV Technologies's G&A increased by 71.8% year-over-year, from $8.5M to $14.6M.
What is the long-term trend for DBV Technologies's G&A?
Over 4 years (2021 to 2025), DBV Technologies's G&A has grown at a 1.8% compound annual growth rate (CAGR), from $30.52M to $32.8M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Ask your AI about DBV Technologies's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude